Acute Myeloid Leukemia (AML)

Myeloablative Conditioning for Allogeneic Transplantation Results in Superior Disease-Free Survival for Acute Myeloid Leukemia and Myelodysplastic Syndromes with Low/Intermediate, but not High Disease Risk Index: A CIBMTR Study: Superior DFS with MAC comp

Myeloablative (MAC) as compared to reduced-intensity conditioning (RIC) is generally associated with lower relapse risk after allogeneic hematopoietic cell transplantation (HCT) for

Treatment Approaches in AML: Key Testing for Personalized Care

Original Publication Date
Article Source
External Web Content
VIDEO Description: Treatment Approaches in AML: Key Testing for Personalized Care from Patient Empowerment Network on Vimeo. When it comes to Acute Myeloid Leukemia (AML), genetic testing (or biomarker testing) is essential in helping to determine the best treatment approach for…

Ryotaro Nakamura, MD

Institution
City of Hope
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Chronic Lymphocytic Leukemia (CLL)
Chronic Myelomonocytic Leukaemia (CMML)
Graft Versus Host Disease (GVHD)
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
Pure Red Cell Aplasia (PRCA)
About
Ryotaro Nakamura, MD is Professor, Department of Hematology & Hematopoietic Cell Transplantation; Director, Center for Stem Cell Transplantation at City of Hope. Since joining City of Hope in 2002, Ryotaro Nakamura, M.D., has been at the forefront of leading-edge research in stem cell transplantation and development of cancer vaccines. Among his promising projects: A study indicating that bone marrow transplants may be effective in treating systemic mastocytosis, a rare blood disease with no known cure, and the use of vaccines to replace antivirals which can often spawn deadly infections. Dr

Talati Highlights “Game-Changing” Potential of Venetoclax/HMA Combos for Elderly AML

Original Publication Date
Article Source
External Web Content
Chetasi Talati, MD, discusses early results from a multicenter chart review examining treatment patterns and outcomes of patients with newly diagnosed AML who received venetoclax/HMA combinations in the real-world setting and the next phase of the ongoing research initiative…

ASH Issues Guidelines on Newly Diagnosed AML in Older Adults

Original Publication Date
Article Source
External Web Content
In evidence-based guidelines issued by the American Society of Hematology and published in the Aug. 11 issue of Blood Advances, recommendations are presented for the management of newly diagnosed acute myeloid leukemia (AML) in older adults. Mikkael A. Sekeres, M.D., from the…

Robert Collins, MD

Institution
Harold C. Simmons Comprehensive Cancer Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
A recognized leader in the field of adoptive immunotherapy, Dr. Collins specializes in blood and marrow transplantation and hematologic malignancies such as leukemia, lymphoma, myeloma, Hodgkin’s disease, and myelodysplasia. Dr. Collins earned his medical degree from the University of Missouri-Kansas City School of Medicine. He completed an internal medicine residency at Baylor University Medical Center in Dallas, as well as a fellowship in hematology and oncology at the University of California at Los Angeles. Board-certified in internal medicine and medical oncology, Dr. Collins has 25 years

Vijaya Bhatt, MD

Institution
University of Nebraska Medical Center
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
Dr. Vijaya Raj Bhatt graduated from Institute of Medicine, Tribhuvan University in Nepal in 2009 with a degree of Bachelor of Medicine and Bachelor of Surgery (MBBS). He then went on to do a three-year residency in internal medicine in Staten Island University Hospital in Staten Island, New York. During his residency, he was awarded the resident of the year for three consecutive years. After completing his residency, he joined the University of Nebraska Medical Center in Nebraska and completed his fellowship in hematology-oncology. He has authored or co-authored 127 articles, 18 book chapters

Pinkal Desai, MD, MPH

Institution
New York Presbyterian Hospital/Weill Cornell Medicine
Physician Status
accepting new patients
Primary Disease Area of Focus
Acute Myeloid Leukemia (AML)
Aplastic Anemia
Myelodysplastic Syndromes (MDS)
Myeloproliferative Neoplasms (MPN)
Paroxysmal Nocturnal Hemoglobinuria (PNH)
About
After obtaining her MBBS at Byramjeejeebhoy Medical College in India in 2005, Dr. Desai obtained an MPH at the University of Alabama at Birmingham School of Public Health. Following her residency at Wayne State University, Detroit Medical Center, she underwent fellowship training in Hematology-Medical Oncology at Providence Hospital Medical Center, serving as Chief Fellow from 2012-2013. Dr. Desai was recruited to serve in our Leukemia Program to develop a clinical practice devoted to leukemia, myelodysplastic syndrome (MDS) and myeloproliferative neoplasms (MPN). She will be developing
Subscribe to Acute Myeloid Leukemia (AML)

Website Feedback

Please use this feedback form to report website issues only. For other issues concerning patients and families, please email help@aamds.org or use the Patient and Family Helpline here.